The author is an analyst for Shinhan Securities. He can be reached at jaewonjeong@shinhan.com -- Ed.Pharmaceutical/bio sector to rebound in 2H23 on favorable macro conditions and progress in new drug pipelinesPharmaceutical/bio stocks have fallen out of investors’ favor with valuations declining on
A nonalcoholic beer has been recalled after the amount of bacteria in it was found to exceed the limit.The Korean Ministry of Food and Drug Safety (MFDS) announced on May 1 that it has suspended the sale of "OB Beer Budweiser Zero" and ordered its recall due to bacterial counts exceeding the standar
NeuroBo Pharmaceuticals, a subsidiary of Dong-A ST, announced on April 4 that it has filed a second phase U.S. Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to develop DA-1241 for the treatment of non-alcoholic steatohepatitis (NASH).The clinical trial w
Dong-A ST announced on Nov. 9 that it has attracted US$32.3 million in investment from NeuroBo Pharmaceuticals under a technology licensing-out and equity investment deal with the U.S. company.In September, Dong-A ST transferred to NeuroBo its exclusive worldwide development and sales rights for DA-
Dong-A ST announced on Sept. 15 that it has signed a global license-out and equity investment contract with NeuroBo Pharmaceuticals of the United States on Sept. 14.Dong-A ST has licensed out DA-1241, a treatment for type 2 diabetes and nonalcoholic steatohepatitis, and DA-1726, a treatment for obes
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed. Hanmi Pharm posted consolidated 2Q22 sales of W316.5bn and OP of W29.6bn, with OP coming in slightly below our estimate. Beijing Hanmi led consolidated OP growth, booking OP of W17.1bn. The strength
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed. Hanmi Pharm posted consolidated 1Q22 sales of W321.1bn and OP of W38.7bn, in line with our estimates, thanks to Beijing Hanmi and business normalization amid the easing of the Covid-19 pandemic. Glob
Hanmi Pharmaceutical announced on Sept. 25 that it presented the results of three studies on potential first-in-class nonalcoholic steatohepatitis (NASH) treatment LAPSTriple Agonist (HM15211) and two studies on first-in-class obesity treatment LAPSglucagon Analog (HM15136) in the 56th meeting of th
Dong-A ST announced on Sept. 22 that the U.S. Food and Drug Administration (FDA) has approved phase 2b/3a clinical trials for repositioning of its diabetes treatment Suganon (component name: Evogliptin) as a medication for calcific aortic valve disease (CAVD), which currently has no other remedy.The
Hanmi Pharmaceutical announced on Aug. 4 that it has licensed out its liver treatment candidate material to leading global drugmaker Merck Sharp Dohme (MSD).Under the agreement, MSD will develop, manufacture and commercialize Hanmi's drug candidate material "LAPSGLP/Glucagon receptor dual agonis
Yuhan Co. announced on Jan. 7 that it has licensed out a new nonalcoholic steatohepatitis (NASH) drug candidate to Gilead Sciences, a global pharmaceutical company known for its product Tamiflu, for US$785 million.Yuhan will receive a down payment of US$15 million (16.7 billion won) from Gilead. Yuh
Domestic pharmaceutical companies, which have been focusing on emerging countries such as Southeast Asia and South America, are stepping up efforts to advance into the US, the world's largest pharmaceutical market.According to industry reports on March 23, Green Cross Corp. recently established
Bain Capital, the world’s largest private equity fund (PEF) firm, will join the 1 trillion won (US$920.13 million) race to acquire CJ Healthcare. The company, which is building its healthcare portfolio, has set up a strategy to maximize a synergy between its acquired firms after buying bio pharmaceu
Hanmi Pharmaceutical Co. announced on September 14 that the two biomedicine candidates using its Acting Protein/Peptide Discovery (LAPSCOVERY) platform technology confirmed the possibility as the treatment for rare diseases through animal testing.LAPSCOVERY is Hanmi’s own platform technology that pr
China Daily, the Beijing-based state-owned English newspaper, arranged an “Incredible China” Tour to explore the ancient historical relics and modern attractions of China. They invited 12 journalists and photographers from eight counties including South Korea, the Philippines, Kazakhstan, Uzbekistan